Physician profile
Patrick J De Marco
NPI 1578598967
$23,054.07
in general payments reported to CMS, 2019-2025
35 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,297 · 2020: $5,126 · 2021: $2,727 · 2022: $1,912 · 2023: $1,843 · 2024: $1,750 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,853 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,852.67 |
| Education | $140.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,609.18 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,650.76 | 2019-2025 | Dupixent |
| Csl Behring | $1,108.42 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,025.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $977.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $675.27 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Optinose US, INC. | $642.17 | 2019-2025 | |
| Genzyme Corporation | $604.17 | 2019-2025 | |
| Grifols USA, LLC | $589.82 | 2019-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Pfizer INC. | $459.06 | 2019-2025 | |
| Genentech USA, INC. | $396.18 | 2019-2025 | Xolair |
| Alk-Abello, INC | $333.45 | 2019-2025 | Ragwitek, Grastek, Odactra |
| Octapharma USA, INC. | $247.68 | 2020-2022 | |
| Kaleo, INC. | $244.10 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.24 | 2019-2023 | Stiolto Respimat |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $210.77 | 2020-2025 | Ruconest |
| Amgen INC. | $196.67 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $172.71 | 2021-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $123.91 | 2021-2025 | |
| Lilly USA, LLC | $55.77 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $53.34 | 2019-2023 | |
| Incyte Corporation | $53.23 | 2022-2025 | Opzelura |
| Biocompatibles, INC. | $50.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.34 | 2019-2021 | |
| Horizon Therapeutics Plc | $43.38 | 2020-2021 | |
| Blueprint Medicines Corporation | $41.98 | 2023-2024 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $41.40 | 2021 | |
| Medtronic Vascular, INC. | $26.87 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.49 | 2025 | Alvesco |
| Boston Scientific Corporation | $24.13 | 2022 | |
| Gc Biopharma USA, INC. | $23.76 | 2025 | Alyglo |
| Galderma Laboratories, L.P. | $22.08 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $19.57 | 2020 | |
| Circassia INC. | $18.64 | 2019 | |
| Hikma Pharmaceuticals USA | $15.13 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick De Marco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.